CCR3 inhibition for ocular neovascularization and macular degeneration - 1476
- Technology Benefits
- Inventionincludes methods for inhibiting the CCR3 receptor or its ligands CCL11, CCL24,or CCL26 in order to treat or prevent ocular angiogenesis andneovascularization. Compared to the current clinical approaches of neutralizingVEGF-A, CCR3 blockade is more effective and not toxic to mouse retina.
- Detailed Technology Description
- None
- *Abstract
-
None
- Country/Region
- USA

For more information, please click Here